[Agonists of beta2 adrenergic receptor in the therapy of obstructive diseases].
Inhaled bronchodilators are a basic element of the pharmacologic management of asthma and COPD. Long-acting beta2-agonists (LABAs) are recommended for use by a majority of recent guidelines as a maintenance treatment in asthma and COPD. It was documented that these medications improve objective measures of lung function and reduce main symptoms of diseases. However inhaled LABAs have been reported to increase some cardiovascular diseases and contribute to the occurrence of arrhythmias. Few studies have documented the sufficient observations to show that LABAs are safe in clinical practice and are still an essential in therapy in patients with obstructive diseases.
Płusa
Tadeusz
T
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000009:adverse effects* / Q000627:therapeutic use*; D000420:Albuterol / Q000009:adverse effects / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D002318:Cardiovascular Diseases / Q000139:chemically induced; D004357:Drug Synergism; D004983:Ethanolamines / Q000009:adverse effects / Q000627:therapeutic use; D000068759:Formoterol Fumarate; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D013726:Terbutaline / Q000009:adverse effects / Q000627:therapeutic use
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D004983:Ethanolamines; D013726:Terbutaline; D000420:Albuterol; D000068759:Formoterol Fumarate